This site uses cookies to bring you the best experience. Find out more
Skip to main content
↑

News

Find Out The Latest

Keep in touch with exciting developments from The Oxford Science Park and its occupiers here.

Contact us on comms@oxfordsp.com if you would like to know more about any of these stories.

You can also follow us on LinkedIn  

Oxford Nanopore and bioMérieux to enter into a strategic partnership agreement to develop innovative infectious disease diagnostics

Oxford Nanopore and bioMérieux to enter into a strategic partnership agreement to develop innovative infectious disease diagnostics

14 Apr 2023

Oxford Nanopore and bioMérieux to enter into a strategic partnership agreement to develop innovative infectious disease diagnostics Fri 14th April 2023 Oxford Nanopore Technologies and bioMérieux SA, a world leader in the field of in vitro diagnostics, today announced that they have teamed up to improve health outcomes globally by exploring selected opportunities to bring nanopore sequencing to the infectious disease diagnostics... Read more

Orbit Discovery and Evergreen Discovery collaborate to discover peptides for targeting radiopharmaceuticals

Orbit Discovery and Evergreen Discovery collaborate to discover peptides for targeting radiopharmaceuticals

03 Apr 2023

New Jersey, USA, and Oxford, UK: Evergreen Discovery (Evergreen), a leading radiopharmaceutical drug development company with a focus on the treatment and diagnosis of cancer, and Orbit Discovery Ltd (Orbit), a leader in the discovery of therapeutic peptide hits, announced today that they have entered into a collaboration to identify specific cell targeting peptides and advance the development of novel radiopharmaceuticals. The agreement covers... Read more

Oxford Cancer Biomarkers closes funding round led by Plutus Investment Group LLP

Oxford Cancer Biomarkers closes funding round led by Plutus Investment Group LLP

03 Apr 2023

OXFORD, UK – 3rd April 2023 – Oxford Cancer Biomarkers Ltd (OCB), a leader in AI-driven, precision cancer diagnostics, has successfully closed its latest investment round. Plutus Investment Group LLP led the round, with participation from new and existing investors including UK-based VC funds Esperante Ventures, Longwall Ventures and Panacea Innovation, alongside entrepreneur and professional investor, Mr BK Lee. Funds will be used to... Read more

NIHR, Oxford Nanopore announce new health study

NIHR, Oxford Nanopore announce new health study

31 Mar 2023

31 March 2023 Oxford Nanopore Technologies plc announces new human health and disease study led by the UK National Institute for Health and Care Research (NIHR) BioResource Oxford Nanopore Technologies plc (LSE: ONT) ("Oxford Nanopore"), the company delivering a new generation of Nanopore-based molecular sensing technology, today announces its participation in a cohort study led by the UK National Institute for Health and Care Research... Read more

Oxford Vacmedix announces completion of Phase 1a in clinical trial of novel cancer vaccine OVM-200

Oxford Vacmedix announces completion of Phase 1a in clinical trial of novel cancer vaccine OVM-200

29 Mar 2023

Oxford Vacmedix announces completion of Phase 1a in clinical trial of novel cancer vaccine OVM-200 The initial part of a Phase I trial of OVM-200, Oxford Vacmedix’s lead cancer vaccine, has been completed – the first clinical trial of a cancer vaccine using novel ROP technology. Oxford, UK – 29th March 2023 Press Release – Oxford Vacmedix announces completion of Phase 1a in clinical trial of novel cancer vaccine OVM-200 Oxford... Read more

The Daubeny Project

Imaginative design, inspiring spaces.

450,000 sq ft of
premium lab space
completing 2026

Discover More